MTOR and systemic lupus erythematosus: Considering previous studies on monocyte gene expression modulation in SLE conditions [16], as well as the established efficacy and safety of sirolimus in SLE patients [17], sirolimus-mediated mTOR inhibition could be considered a potential therapeutic strategy in the management of SLE-related inflammation.